



GALIEN FOUNDATION

PRIX GALIEN USA

GALIEN FORUM

TUESDAY, SEPTEMBER 27, 2011

8:30 AM - 1:00 PM

ALEXANDRIA CENTER™ FOR LIFE SCIENCE -
NEW YORK CITY

450 EAST 29TH STREET, 2ND FLOOR
(BETWEEN 1ST AVENUE AND THE EAST RIVER)
APELLA™, EVENT SPACE AT ALEXANDRIA CENTER™

AWARDS COMMITTEE

MICHAEL S. BROWN, M.D. *
UT Southwestern Medical Center at Dallas

WALTER GILBERT, PH.D. *
Harvard University

JOSEPH GOLDSTEIN, M.D. *
UT Southwestern Medical Center at Dallas

PAUL GREENGARD, PH.D. *
Rockefeller University

ERIC R. KANDEL, M.D. *
Columbia University

RICHARD A. LERNER, M.D.
Scripps Research Institute

PAUL A. MARKS, M.D.
Memorial Sloan Kettering Cancer Center

BENGT SAMUELSSON M.D. PH.D. *
Nobel Foundation, Karolinska Institute

JAN T. VILCEK, M.D.
New York University School of Medicine

ELIE WIESEL *
Honorary Member, Boston University

GERALD WEISSMANN, M.D.
New York University School of Medicine
Committee Chairman

* Nobel Laureate

*The Galien Foundation is a not-for-profit,
501(c)(3) public charity.*

REGISTRATION: 8:00 AM

SESSION I: 8:30 - 10:30 AM

ROUNDTABLE IA

Funding Innovation

New Trends in the Healthcare M&A Landscape

(Co-sponsored by Biopharm Insight, part of the Financial Times Group and by Proskauer)

Leading Life Science business executives, investors and advisors in the biomedicine field will discuss trends and developments in the healthcare M&A landscape, including today's best exit strategies and the pros and cons of a partnership versus an M&A deal. What impact will these different strategies have on the continued development of company pipelines? will join Moderator **Kimberly Ha**, *Global Editor, Biopharm Insight*:

Jaime Burnes, *Managing Director, Healthcare Investment Banking, Cowen Group*
Les Funtleyder, MPH, *Healthcare Strategist and Portfolio Manager, Miller Tabak Health Care Transformation Fund*

William Kridel, *Managing Director at Ferghana Partners, a specialist investment banking group*

Paul I. Rachlin, *Partner, Proskauer*

Jonathan Silverstein, *Partner, OrbiMed Advisors*

Jide Zeitlan, *CEO, Keffi Group*

ROUNDTABLE IB

What is "Value" and How Can it be Measured and Demonstrated in Therapeutic Innovations?

Breaking Down the Barriers of the Past

Historically, pharmaceutical companies and payers have operated more independently than not. But with insurers facing demands for greater value and lower costs, neither side can ignore the other anymore. Value will depend on endpoints like appropriate utilization, clinical effectiveness as well as costs. What new approaches are likely to emerge? What will be the role of value-based risk-sharing agreements? How can payers and industry R&D organizations better work together? Panelists will join Moderator **Richard C. Pasternak, MD**, *former Merck & Co., Inc vice president. and past director, Preventive Cardiology Massachusetts General Hospital and Harvard Medical School associate professor, to discuss these challenges.*

Jeffery Berkowitz, *SVP Pharmaceutical Development and Market Access at Walgreens*

Robert S. Epstein M.D., *Chief Clinical Research and Development Officer, Medco Health Solutions, Inc.*

Barry Gertz, MD, PhD., *SVP at Merck, and head of clinical research and regulatory affairs*

Roger Longman, *CEO, Real Endpoints*

Peter J. Pitts, *President, Center for Medicine in the Public Interest*

COFFEE BREAK: 10:30 - 11:00 AM

Register on our website: forum.galienfoundation.org



GALIEN FOUNDATION

PRIX GALIEN USA

SESSION II: 11:00 AM - 1:00 PM

ROUNDTABLE IIA

The Next Generation of Health and Research Informatics

Accelerating Translational Research & Personalized Medicine at Moffitt Cancer Center
(Sponsored by Oracle)

Much of the dialogue around personalized medicine focuses on the scientific and biotechnology breakthroughs we have witnessed in recent years, as well as the ethical, regulatory and reimbursement challenges facing organizations commercializing these breakthroughs. However, achieving the promise of personalized medicine is about fundamentally transforming healthcare – from the way we conduct research through to patient care. This transformation is only possible through the synergy of healthcare information technology (HIT) with scientific breakthroughs in the molecular understanding of disease as well as a fundamental redesign of healthcare delivery. Leveraging data from numerous clinical sources, a state-of-the-art biobank and patient-reported outcomes from across the healthcare ecosystem will be essential. Panelists from the Moffitt Cancer Center will include:

Moderator: **Brett Davis**, Senior Director, Personalized Healthcare, Oracle Corporation, Health Sciences Global Business Unit

Mark Hulse, RN, Vice President Information Technology and Chief Information Officer, Moffitt Cancer Center

Dana Rollison, Ph.D., Vice President, Total Cancer Care and Chief Health Information Officer, Moffitt Cancer Center

Robert M. Wenham, MD, MS, FACOG, FACS, Principal Investigator, Total Cancer Care Programs of Gynecologic Oncology & Experimental Therapeutics Moffitt Cancer Center

ROUNDTABLE IIB

A Global Health Challenge: The Obesity and Diabetes Epidemic

Where are the Innovations and Who Will Pay For Them?

(Sponsored by Alexandria Real Estate Equities, Inc.)

Obesity and diabetes numbers are rising around the world. The anticipated cost burden is equally alarming. What interventions are needed to help curb the epidemic? Who will pay for their development, and how can we ensure access for those who need it most?

Panelists will join Moderators **Ron Winslow**, Senior Medical and Health Care Writer, *WSJ Deputy Editor, Health and Science* and **Lynne Zydowsky, PhD**, President, *Zydowsky Consultants*

Stephen Daniels, MD, PhD, MPH, Professor and Chair, Department of Pediatrics, University of Colorado School of Medicine, Pediatrician-in-Chief, *L Joseph, Butterfield Chair in Pediatrics, Children's Hospital Colorado*

Alex DePaoli, MD, Vice President of Translational Research, *NGM Biopharmaceuticals*

Martin Fitchet, MD, Chief Operating Officer, *Johnson & Johnson, Pharmaceutical Research & Development*

Jeffrey Friedman, MD, PhD, Marilyn M Simpson Professor, Investigator *Howard Hughes Medical Institute, Laboratory of Genetics, The Rockefeller University*

Magnus Persson, MD, PhD, Managing Partner, *The Column Group*

Francesco Rubino, MD, Associate Professor of Surgery, Director, *Metabolic & Diabetes Surgery Center, Weill Cornell Medical College*

ROUNDTABLE IIC

Perspectives on Innovation, Patient Safety and Global Access

Thinking Beyond Laboratories and Clinical Trials

Say “innovation” or “patient safety” and many in the health community think laboratories and clinical trials. However, these markers of traditional innovation will not be enough to fulfill an expansive mission of improving health worldwide. This panel will offer perspectives on innovating around the individual patient, the global healthcare environment, and how patients and government health systems understand risks and benefits. Panelists will explore the collaborative roles of the healthcare community, governments, NGOs, academic medical centers and industry. Panelists will join Moderator **Michael Rosenblatt, MD**, Executive Vice President and Chief Medical Officer, *Merck & Co., Inc.*

Peter D. Loftus, *Dow Jones Newswires reporter covering pharmaceutical industry; contributor to Wall Street Journal*

Steven Nissen, M.D., M.A.C.C., Chairman, Department of Cardiovascular Medicine *Cleveland Clinic Foundation and Professor of Medicine, Cleveland Clinic Lerner School of Medicine at Case Western Reserve U.*

Larry Norton, MD, Deputy physician-in-chief for breast cancer programs and medical director, *Evelyn H. Lauder Breast Center, Memorial Sloan-Kettering Cancer Center*

Mark Pykett, President and Chief Executive Officer, *Neoprobe Corporation*

Kevin Tabb, MD, chief medical officer, *Stanford Hospital & Clinics.*

Kevin Tabb, MD, chief medical officer, *Stanford Hospital & Clinics.*

Kevin Tabb, MD, chief medical officer, *Stanford Hospital & Clinics.*

Register on our website: forum.galienfoundation.org

AWARDS COMMITTEE

MICHAEL S. BROWN, M.D. *
UT Southwestern Medical Center at Dallas

WALTER GILBERT, PH.D. *
Harvard University

JOSEPH GOLDSTEIN, M.D. *
UT Southwestern Medical Center at Dallas

PAUL GREENGARD, PH.D. *
Rockefeller University

ERIC R. KANDEL, M.D. *
Columbia University

RICHARD A. LERNER, M.D.
Scripps Research Institute

PAUL A. MARKS, M.D.
Memorial Sloan Kettering Cancer Center

BENGT SAMUELSSON M.D. PH.D. *
Nobel Foundation, Karolinska Institute

JAN T. VILCEK, M.D.
New York University School of Medicine

ELIE WIESEL *
Honorary Member, Boston University

GERALD WEISSMANN, M.D.
New York University School of Medicine
Committee Chairman

* Nobel Laureate

The Galien Foundation is a not-for-profit,
501(c)(3) public charity.